Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center

National organizations recommend screening for hepatitis B virus (HBV) before chemotherapy but differ regarding which patients should be screened. We aimed to determine contemporary screening rates at a cancer center and the possible influence on these rates of publication of national recommendation...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2013-11, Vol.13 (1), p.534-534, Article 534
Main Authors: Hwang, Jessica P, Fisch, Michael J, Lok, Anna S-F, Zhang, Hong, Vierling, John M, Suarez-Almazor, Maria E
Format: Article
Language:English
Subjects:
Adult
Age
Aged
Analysis
Antiviral agents
Cancer
Cancer Care Facilities
Care and treatment
Chemotherapy
Clinical trials
Codes
Diagnosis
Disease control
Drug therapy
Ethnicity
Female
Health aspects
Hepatitis
Hepatitis B
Hepatitis B - complications
Hepatitis B - diagnosis
Hepatitis B - epidemiology
Hepatitis B virus
Humans
Infections
Internal medicine
Laws, regulations and rules
Liver
Liver cancer
Male
Mass Screening
Medical screening
Medicine
Methods
Middle Aged
Neoplasms - complications
Neoplasms - drug therapy
Oncology
Oncology, Experimental
Patients
Prevention
Retrospective Studies
Risk Factors
Studies
Trends
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:National organizations recommend screening for hepatitis B virus (HBV) before chemotherapy but differ regarding which patients should be screened. We aimed to determine contemporary screening rates at a cancer center and the possible influence on these rates of publication of national recommendations. We conducted a retrospective cohort study of HBV screening in cancer patients registered during the period from January 2004 through April 2011. Screening was defined as HBsAg and anti-HBc tests ordered around the time of initial chemotherapy. We compared screening rates for 3 periods: January 1, 2004, through December 18, 2008 (Food and Drug Administration and American Association for the Study of Liver Diseases 2007 recommendations); December 19, 2008, through September 30, 2010 (Centers for Disease Control and Prevention, National Comprehensive Cancer Network, American Association for the Study of Liver Diseases 2009, Institute of Medicine, and American Society of Clinical Oncology recommendations); and October 1, 2010, through April 30, 2011. Logistic regression models were used to identify predictors of screening. Of 141,877 new patients, 18,688 received chemotherapy, and 3020 (16.2%) were screened. HBV screening rates increased over the 3 time periods (14.8%, 18.2%, 19.9%; P
ISSN:1471-2407
1471-2407
DOI:10.1186/1471-2407-13-534